Alvogen and Pfenex have agreed to expand their existing US collaboration on Pfenex’ PF708 teriparatide candidate to also encompass the EU, certain MENA countries and other international markets.
Alvogen and Pfenex’ collaboration agreement on Pfenex’ PF708 teriparatide candidate has been expanded from the US to also cover the EU, certain Middle East and North Africa (MENA) countries and other international markets. However, the deal excludes China, Hong Kong, Malaysia, Singapore and Thailand.
The initial deal struck last year gave Alvogen exclusive US commercial rights to PF708, a rival to Eli Lilly’s Forteo/Forsteo...
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.
